Enlivex Therapeutics Ltd.

Enlivex Therapeutics is a clinical-stage immunotherapy company developing a novel class of macrophage reprogramming therapies. Its proprietary platform, Allocetra™, is an allogeneic, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state, effectively rebalancing a life-threatening or chronic unbalanced immune system without suppressing it. The company's primary focus is on treating conditions characterized by immune system hyper-responses, such as sepsis and solid tumors, as well as chronic inflammatory conditions like osteoarthritis. By engaging macrophages and dendritic cells, Allocetra™ aims to avert cytokine storms and restore immune balance. Enlivex is currently advancing multiple clinical programs, with significant recent milestones in knee osteoarthritis and sepsis.